



Alpa Laboratories Ltd.

33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India

Phone No. : +91-731- 429 4567 Fax No. : +91-731- 429 4444

Email : mail@alpalabs.in

CIN L85195MP1988PLC004446

Date: -26th May, 2018

To,
Listing Department,
BSE Limited.
Rotunda Building, P J Towers
Dalal Street, Fort,
Mumbai - 400 001
BSE Code: 532878

To,
Listing Department,
National Stock Exchange of India Limited.
Exchange Plaza', C-1, Block G,
Bandra - Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Code: ALPA

Subject: Outcome of Board Meeting under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

This is to inform you that pursuant to provisions of Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the meeting of the Board of Directors of the Company was held today that is on **Saturday, 26th May, 2018** at registered office of the Company situated at 33/2, A.B Road, Pigdamber Rao, Indore, Madhya Pradesh has approved the following matter:

1. Approval of Standalone & Consolidated Audited Financial Results of the Company for quarter and year ended 31st March, 2018 .

The Board meeting commenced at 4.00 P.M and concluded at 9.50 P.M.

Please find enclosed herewith the copy of approved **Standalone & Consolidated Audited Financial Results of the Company for quarter and year ended 31st March, 2018.**

Kindly take same for your records and oblige.

Thanking you,

Yours Faithfully

For ALPA LABORATORIES LIMITED

For ALPA LABORATORIES LIMITED

Megha Neema


Company Secretary

COMPANY SECRETARY AND COMPLIANCE OFFICER

Financial Results for Quarter ended 31st March 2018

(Rs. in lacs except EPS)

Particulars	Standalone Results					Consolidated Results	
	Quarter Ended			Year Ended		Year Ended	
	Mar-18	Dec-17	Mar-17	Mar-18	Mar-17	Mar-18	Mar-17
	Unaudited			Audited		Audited	
1. Income							
a) Revenue from operations	1,790.78	1,664.06	1,989.21	6,226.82	6,338.08	6,284.68	6,345.15
b) Other Income	47.78	139.99	304.64	451.44	658.40	463.50	513.70
1. Total income from operations (net) (a+b)	1,838.56	1,804.05	2,293.85	6,678.26	6,996.49	6,748.19	6,858.85
2. Expenses							
a) Cost of materials consumed	991.46	911.21	1,054.34	3,304.56	3,419.07	3,304.56	3,419.13
b) Purchases of stock-in-trade	64.89	-	-	226.66	160.27	283.51	160.27
c) Changes in inventories of fin. goods, stock-in-pro. &	59.24	(46.86)	282.24	31.07	52.94	31.07	52.94
d) Employee benefits expense	287.17	250.81	268.37	1,025.56	861.81	1,025.56	867.21
e) Finance costs	15.05	28.47	27.19	107.15	170.95	107.15	170.95
f) Depreciation and amortization expense	32.39	32.64	20.69	112.89	76.08	315.15	278.33
g) Other expenses							
Manufacturing & Operating	85.59	81.35	88.07	357.32	330.14	357.32	330.14
(Stores and spares consumed, power &							
Others	403.63	159.48	210.58	853.32	803.33	855.05	804.51
Total expenses	1,939.43	1,417.10	1,951.48	6,018.53	5,874.58	6,279.36	6,083.47
3. Profit/(Loss) before exceptional items and tax (1-2)	(100.87)	386.95	342.37	659.73	1,121.91	468.83	775.37
4. Exceptional Items	-	-	-	-	211.53	-	211.53
5. Profit/ Loss(-) before tax (3+/-4)	(100.87)	386.95	342.37	659.73	910.38	468.83	563.85
6. Tax (Expenses)/ Benefit							
Current tax	(188.93)	-	293.00	(188.93)	(285.93)	(193.84)	(285.93)
Deferred tax	10.49	-	-	10.49	(25.81)	10.49	(25.81)
7. Profit/ Loss(-) for the period (5-/+6)	(279.31)	386.95	49.37	481.30	598.64	285.48	252.11
8. Other Comprehensive Income							
(i) (a) Items that will not be reclassified to profit or loss	-	-	-	-	-	-	-
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-	-	-
Total Other comprehensive (loss)/ income (net of tax)	-	-	-	-	-	-	-
9. Total comprehensive income for the period (16+17)	(279.31)	386.95	49.37	481.30	598.64	285.48	252.11
10. Paid-up equity share capital (Face Value `10 Each)	2,104.06	2,104.06	2,104.06	2,104.06	2,104.06	2,104.06	2,104.06
11. Other equity (excluding revaluation reserve)	-	-	-	8,223.49	7,742.19	7,654.18	7,368.70
12. Debenture Redemption Reserve	-	-	-	-	-	-	-
13. Basic and Diluted Earnings per share after extraordinary items (not annualized)	(1.33)	1.84	0.23	2.29	2.85	1.36	1.20



For Alpa Laboratories Limited
Sankar
 Managing Director

Annexure IX Statement of Assets and Liabilities

Particulars	Standalone		Consolidated	
	Mar-18	Mar-17	Mar-18	Mar-17
	Audited	Audited	Audited	Audited
ASSETS				
Non-current assets				
(a) Property Plant and Equipment	602.58	518.17	602.58	518.17
(b) Capital Work-in-progress	-	-	-	-
(c) Investments Property	-	-	-	419.05
(d) Goodwill	-	-	404.50	606.75
(e) Other Intangible Assets	-	-	-	-
(f) Intangible Assets under development	-	-	-	-
(g) Biological Assets other than bearer Plants	-	-	-	-
(h) Investments in subsidiaries, associates and joint venture	2,370.15	1,555.10	1,291.54	478.54
(b) Financial Assets				
(i) Investment	1,770.79	793.34	1,770.79	793.34
(ii) Trade receivables	-	-	-	-
(iii) Loans	-	-	-	-
(iv) Others	42.20	27.65	42.20	27.65
(i) Deferred tax assets (net)	76.13	65.64	76.13	65.64
(j) Other non-current assets	50.04	43.71	50.04	43.71
Sub-total - Non-current assets	4,911.89	3,003.61	4,237.78	2,952.86
Current Assets				
(a) Inventories	1,372.30	1,303.88	1,372.30	1,303.88
(b) Financial Assets				
(i) Investment	-	-	-	-
(ii) Trade receivables	2,544.16	2,916.08	2,602.02	2,916.08
(iii) Cash and Cash Equivalents	13.50	123.00	19.03	238.33
(iv) Bank Balances other than (iii) above	2,115.06	3,430.00	2,115.06	3,430.00
(v) Short term loans & advances	468.73	1,002.30	706.46	716.34
(vi) Others	72.14	53.78	72.14	53.78
(c) Current Tax Assets (Net)	-	-	-	-
(d) Other current assets	1,365.87	1,198.74	1,232.27	1,065.72
Sub-total - Current assets	7,951.77	10,027.77	8,119.28	9,724.13
TOTAL - ASSETS	12,863.66	13,031.38	12,357.06	12,676.99
EQUITY AND LIABILITIES				
Equity				
(a) Equity Share capital	2,104.06	2,104.06	2,104.06	2,104.06
(b) Other Equity	8,223.49	7,742.19	7,654.18	7,368.70
Sub-total - Equity	10,327.55	9,846.25	9,758.24	9,472.76
Liabilities				
Non-current liabilities				
(a) Financial Liabilities				
(i) Borrowings	18.67	46.90	18.67	46.90
(ii) Trade Payables	-	-	-	-
(iii) Other Financial Liabilities	64.97	62.77	64.97	62.77
(b) Provisions				
(c) Deferred Tax Liabilities (Net)	-	-	-	-
(d) Other Non-current Liabilities	-	-	-	-
Sub-total - Non-current liabilities	83.64	109.66	83.64	109.66
Current liabilities				
(a) Financial Liabilities				
(i) Borrowings	517.80	1,016.07	517.80	1,016.07
(ii) Trade Payables	1,261.89	1,393.37	1,319.01	1,393.82
(iii) Other Financial Liabilities	113.72	60.57	113.72	60.57
(b) Other Current Liabilities	242.43	328.67	247.79	347.15
(c) Provisions	316.64	276.80	316.87	276.97
(d) Current Tax Liabilities (Net)	-	-	-	-
Sub-total - Current liabilities	2,452.48	3,075.47	2,515.19	3,094.57
TOTAL - EQUITY AND LIABILITIES	12,863.66	13,031.38	12,357.06	12,676.99

Notes -

- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, read with rule 3 of the Companies (Indian accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Accounting
 - The figures for the quarter ended 31/02.2018 and 31.03.2017 represent the balance between the audited figures in respect of the full financial years and those published till the third quarter of the respective financial years.
 - The Company is operating in the single segment of Drugs & Chemicals.
 - The Figures of Previous Year/ Periods may have been regrouped/ reclassified wherever necessary.
 - Application for merger of Norfolk Mercantile Private Limited, Wholly owned subsidiary of Alpa laboratories Limited was filed before NCLT, Mumbai by Norfolk Mercantile Private Limited on 7th December, 2017. The same was approved by the Bench vide Order dated 15th December, 2017. Application was also filed by Alpa laboratories Limited before NCLT Ahmedabad on 15th January, 2018. Against the application an order was issued by the Bench on 2nd February, 2018 for approval of the same in EGM by the Shareholders through Special Resolution. The EGM was conducted on 7th of May, 2018 which approved the same. The Scrutinizer report and the Chairman report was filed on 9th May, 2018. Final petition was filed before the Bench on 15th May, 2018.
- BSE Limited has informed the company through letter dated 8th March, 2018 that a notice has been received by them from one of the advocates on 28th February, 2018 eluding some dispute on title of Equity Shares of Norfolk Mercantile Private Limited. Alpa Laboratories Limited will be filing requisite reply on the same.



For Alpa Laboratories Limited
[Signature]
 Managing Director



INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Alpa Laboratories Limited,

1. We have audited the accompanying Statement of Standalone Financial Results of Alpa Laboratories Limited (the Company), for the year ended March 31, 2018 (the Statement), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related standalone financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS') and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such standalone financial statements.
3. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanations given to us, the statement:
 - (i) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,
 - (ii) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and Total comprehensive income and other financial information of the Company for the year ended March 31, 2018.

For and on behalf of
ANURADHA RATNAPARKHI & ASSOCIATES
Chartered Accountants
Firm Registration No.: 0023451C


ANURADHA RATNAPARKHI
Proprietor
Membership No.: 75412



Place: Indore

Date: This 26th day of May, 2018